VACCINE ADJUVANTS: ENHANCING IMMUNE RESPONSE IN LIVESTOCK VACCINATION

Muhammad Muzammil NAZIR

Asma ASHRAF

Derya Karatas YENI

Vaccines are vital agents in the fight against infectious illnesses in animals. The majority of the components of next-generation veterinary vaccines will be either subunit or inactivated bacteria or viruses. The choice of an appropriate adjuvant that promotes the activation of adaptive immune responses is one of the most crucial phases in the creation of vaccines. The creation of novel and enhanced veterinary vaccine adjuvants that promote the right immunity—such as T cell immunity for intracellular infections and cancer vaccines—is desperately needed. Structure–function relationships that are helpful in the development of novel adjuvants have been established in a number of adjuvants through the identification of chemical groups that interact with particular cell toll-like receptors (innate immunity) or receptors for co-stimulatory ligands (adaptive immunity). Adjuvants are substances, mixtures, or macromolecules that boost non-specific immunity and, when combined with one or more antigens, can modify the nature of the immune response as well as strengthen it. To give the safest stimulation, adjuvants' potential and toxicity must be matched. Based on their main modes of action, adjuvants can be generally classified into two classes: "immunostimulatory adjuvants" and vaccine delivery methods. Vaccine delivery vehicles, such as emulsions, microparticles, ISCOMS, and liposomes, are typically particulate and serve the primary purpose of delivering associated antigens to antigen-presenting cells (APCs). On the other hand, immunostimulatory adjuvants, which activate innate immune system cells, are mostly obtained from pathogens and frequently represent pathogen linked molecular patterns, such as LPS, MPL, and CpG DNA. Adjuvants available on the market and experimental mixtures that focus on mineral salts, emulsions, components produced from bacteria, saponins, and various other immunoactive substances. Furthermore discussed are the various adjuvants' modes of action, instances of adjuvant combinations in a single vaccine formulation, and difficulties encountered during the study and creation of adjuvants for veterinary vaccines. According to certain research, nanoparticles exhibit a remarkably greater capacity for adjuvant action than microparticles. Nanoparticles also work better in targeted antigen delivery because they can more easily pass through biological barriers than nanoadjuvants, which inactively target antigen-presenting cells (APCs) and alter their chemical surface. Adjuvants for immunity work by boosting particular immune responses to vaccinations. Adjuvants, such as copolymer adjuvants, can affect various aspects of immune responses, such as the type of cell-mediated immunity, the frequency of genetic non-responders, and the specificity, titer, duration, memory, class, isotype, and avidity of antibodies. A more sophisticated approach to the study of adjuvants as agents is encouraged. Adjuvants are needed in order to elicit an immunological response from inactivated vaccinations. Whether the immunological response is beneficial, detrimental, or ineffectual depends on the adjuvant or immune enhancer selected.

1. Introduction

One of the best and most affordable methods of preventing a wide range of infectious diseases is vaccination. It seeks to provide persistent protection against infection and elicit an immune response unique to the pathogen (Lee & Nguyen, 2015). Conventional vaccines consisting of live attenuated or inactive pathogens can effectively and long-lastingly stimulate the immune system; however, these vaccines come with a number of safety concerns, such as the potential for partial or full antigen inactivation or mutations that could restore pathogenicity. Subunit vaccinations, on the

other hand, are less immunogenic but safer. Thus, adjuvants are required for subunit vaccinations in order to boost immunogenicity (Park et al., 2016). According to Lee and Nguyen (2015), adjuvants are substances that are added to vaccination formulations in order to boost the immunogenicity of antigens. They allow immunization programs to utilize fewer doses of vaccine and facilitate the use of smaller antigen doses (Coffman et al., 2010). Adjuvants also lessen the possibility of vaccines degrading after injection or storage, which contributes to their increased durability. They also affect how quickly, strongly, and long-lasting the immune responses are (Schijns & Lavelle, 2011).

According to (Aucouturier et al., 2001), the best way to keep farm animals safe from infectious disease losses is to vaccinate them widely. Historically, the main components of veterinary vaccinations have been live attenuated pathogens, fully inactivated organisms, or inactivated bacterial toxins (Chroboczek et al., 2014). These methods have generally been effective in the development of vaccines because they induce the production of antibodies that neutralize viruses or bacterial toxins, prevent germs from attaching to cells, or encourage phagocyte absorption of the microbes. Even while veterinary vaccines contain attenuated variants of the disease, there are still worries that these could occasionally return to the virulent form. As an alternative to these vaccines, using killed organisms or sections of them offers a lower level of protection than attenuated forms. Furthermore, it has been generally shown that non-living vaccines are poor at eliciting strong cell-mediated immunity (CMI), especially Th1-specific CMI. Th1 responses are distinguished by the generation of g interferon (IFN), and Th2 responses are mostly based on the cytokine production of T helper cells in mice. Furthermore, Live attenuated vaccines can also infect immunocompromised animals, and many viruses are difficult to cultivate in culture, making the creation of inactivated vaccines impractical. However, live immunizations can trigger the formation of cytotoxic T lymphocytes (CTL) (Bowersock & Martin, 1999).

The 1800s saw the introduction of vaccination, which offered previously unheard-of advantages for veterinary and human medicine. Many illnesses that once plagued humans and animals are now under control or prevented via vaccinations, including poliomyelitis, smallpox, distemper, and parvovirus enteritis. The accomplishments of early vaccine scientists like Pasteur and Jenner are widely acknowledged. Parallel discoveries that increased the effectiveness and, in certain circumstances, even feasibility of vaccination is less frequently reported. In the 1920s, (Ramon, 1925) discovered that horses with injection site abscesses had higher antibody titers after vaccination. Later, he and other researchers found that compounds made of tapioca, agar, lecithin, saponin, and aluminum could all be injected to increase titers (Ramon, 1926) Freund et al. (Freund et al., 1937) developed a very potent mixture of water, mineral oil, and killed mycobacteria in the 1930s. These findings served as the foundation for the creation of adjuvants, which are immune-boosting vaccination additives.

Any material that, an immunologic adjuvant is a substance that is added to a vaccine formulation with the overall purpose of accelerating, prolonging, or enhancing certain immune responses to immunization antigens. The Latin verb adjuvare, which meaning to assist or support, is the root of the English word adjuvant Adjuvant mechanisms of action include extending the biological or immunologic half-life of vaccine antigens, improving antigen delivery to antigen-presenting cells (APCs), facilitating the processing and presentation of antigens by APCs, and inducing the production of immunomodulatory cytokines (Lindblad et al., 1997). By modifying cytokine responses, adjuvant formulations can be produced that encourage the development of T-helper type 1 (Th1) or type 2 (Th2) immune responses to vaccine antigens. The use of new adjuvants in conjunction with human candidate vaccines, such as experimental subunit vaccines against tuberculosis, is now being studied in preclinical and clinical studies (Freund et al., 1937). To aid in the clinical evaluation of novel adjuvants, standardized preclinical adjuvant-safety tests are also being developed. Adjuvants for immunology have been produced and tested throughout the majority of this century. In the mid-1920s, Ramon reported that horses with abscesses established at the site of a diphtheria toxoid injection produced higher antitoxin titers than animals without

abscesses. Subsequently, he revealed that abscesses in horses caused by injecting foreign chemicals alongside toxoid also increased their antitoxin responses. Using an alum-precipitated diphtheria toxoid vaccine, Glenny (AT, 1926) showed the adjuvant action of aluminum compounds in 1926. Freund (Freund et al., 1937) created a potent immunologic adjuvant in the middle of the 1930s that was made of a water-in-mineral-oil emulsion and included dead mycobacteria as an extra immunomodulator.

Despite being one of the most powerful adjuvants available, Freund's complete adjuvant (FCA) is extremely reactogenic and therefore unsuitable for use in human vaccines. Nonetheless, Freund's incomplete adjuvant—which is devoid of mycobacteria—was utilized in a UK-licensed influenza vaccination and is currently being tested in multiple HIV vaccines. The adjuvant activity of gram-negative bacteria's endotoxins was originally noted by Arthur Johnson in 1956 (O'HAGAN, 1998). In 1974, Ellouz et al. (Ellouz et al., 1974) discovered that muramyl dipeptide was the smallest adjuvant active component of the mycobacteria in Freund's complete adjuvant. Currently, vaccinations based on aluminum salts are the only immunologic adjuvants used in US-licensed products. Nonetheless, hundreds of artificial and natural substances with adjuvant properties have been found. For several decades, a number of these innovative adjuvants have been developed and evaluated in preclinical settings, with the potential to supplement or replace alum in human vaccinations (Vogel & Powell, 1995). Many new adjuvants have been shown to enhance both antibody and cell-mediated immune responses to vaccination antigens more effectively than alum in animal models. Clinical trials comparing the efficaciousness of different adjuvants have been started, and extensive preclinical testing of innovative immunologic adjuvants has been carried out. "Substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone" was how Ramon (1924) first defined immunological adjuvants. A very large range of materials are covered by this broad concept (Vogel & Powell, 1995). However, the primary adjuvant now approved for human use by the US Food and Drug Administration is based on mineral salts containing aluminum (often referred to as alum), despite rigorous study of a vast variety of alternatives over many years. Although alum has a solid safety record, research comparing the effects on people and animals indicate that it is a weak adjuvant for recombinant protein vaccine-induced antibody production and that it generates a Th2 response as opposed to a Th1 response. Since safety issues have impeded the development of numerous adjuvants since the introduction of Freund's adjuvant and alum more than 50 years ago, toxicity is a critical issue in adjuvant development (Bowersock & Martin, 1999). Although a large number of experimental adjuvants have progressed to animal studies and some have shown great potency, the majority have shown to be too toxic for everyday use. The reactogenicity of the injection site, the adjuvant's removal or biodegradation, and the length of retention at the injection site are some of the key factors that may dictate the usage of these chemicals for veterinary purposes. Adjuvants that cause only minor local and systemic side effects will be approved for use in conventional prophylactic immunization in healthy animals. Adjuvant development also needs to consider practical factors such stability, simplicity of manufacture, cost, and suitability for a variety of vaccines. A few instances of the several adjuvant classes under evaluation for use in human and animal vaccinations against infectious diseases (Bowersock & Martin, 1999).

2. The Discovery of Adjuvants

The finding that an adjuvant added to a vaccine can boost immunity was coincidental, as is the case with many significant medical discoveries. Horses with an abscess at the injection site produced more tetanus and diphtheria anti-sera, according to French veterinarian Gaston Ramon's observations (Di Pasquale et al., 2015). He injected starch, breadcrumbs, or tapioca to create sterile abscesses at the injection site using inactivated toxin, which increased the production of anti-sera. This supported the theory that chemicals that might aggravate the injection site locally might also boost anti-sera yield. Alexander Glenny discovered aluminum salts' immune-boosting qualities about the same time he was conducting research in London with associates. The year 1932 saw the

introduction of aluminum as the sole adjuvant in human vaccines, a position it held for about seventy years. Aluminum's immunological mode of action is still not well known, despite its widespread and ongoing use (Marrack et al., 2009). Aluminum adjuvants are appropriate for vaccinations that target pathogens that are mostly eliminated by antibodies since they primarily work to enhance the formation of antibodies. Intracellular pathogen infection has not been successfully prevented by aluminum-adjuvanted vaccinations. Freund's incomplete adjuvant, a mineral oil-in-water emulsion, was another early effort at an adjuvant and was deemed too reactogenic for continuous usage in humans. Adjuvants are currently found in more than 30 licensed vaccinations from various manufacturers and have been used for more than 90 years. Adjuvants are not required for all vaccines. Because they cause a mild infection in recipients and elicit an immune response akin to that caused by infection with wild-type strains, live-attenuated vaccines are effective because they can trigger innate immunity, which in turn triggers adaptive responses that successfully eradicate the pathogen. A heterogeneous blend of different antigens and other pathogen components that function as intrinsic adjuvants have made some inactivated whole-pathogen vaccinations effective. These vaccinations are not appropriate, nevertheless, in situations where the pathogen cannot be cultured in culture or in which the natural infection does not produce lifelong protection (Coffman et al., 2010).

3. Major Types of Adjuvants

There are hundreds of compounds having adjuvant activity that have been discovered since the first adjuvants were discovered in the 1920s. Many of the adjuvants that identified are still in use. The only adjuvants permitted in human immunizations until recently were alum compounds. Animal vaccinations were made with both oil and alum emulsions. Sometimes a powerful adjuvant is needed and inflammation is not a major adverse effect, Freund's incomplete adjuvant (FIA), which is devoid of mycobacteria, is employed. Because of its toxicity, Freund's original emulsion—known as Freund's complete adjuvant, or FCA—was discontinued. Recently, there has been a greater focus on novel adjuvants that have the potential to induce CMI or more powerful immune responses with fewer side effects. There are some vaccines that use proprietary adjuvants, the details of which are not made public (AT, 1926).

4. Role of adjuvants in veterinary vaccine development

Several strategies can be employed with adjuvants to modify antibody avidity, specificity, isotype, or subclass distribution; (1) boost weak antigens' immunogenicity; (2) accelerate and prolong the immune response; (3) activate CTL; (5) encourage the development of mucosal immunity; (6) boost immune responses in immunologically immature or senescent individuals; (7) lower the dose of antigen in the vaccine to lower costs; or (8) help overcome antigen competition in combination vaccines (Freund et al., 1937).

5. Types of Immunologic Adjuvants

Adjuvants for immune function can be categorized based on their sources, modes of action, and chemical or physical characteristics. Examples of adjuvant types being developed and tested for use with human vaccinations are shown in Table 1.

Table 1. Different classes of adjuvants for enhancing immune response to vaccines in animals

Immunostimulatory adjuvants	Cytokines, e.g. lL-2, IL-12, GM-CSF, saponins, (e.g. QS21), MDP derivatives, bacterial DNA (CpG oligos), LPS, MPL and synthetic derivatives, lipopeptides
Mineral salts	Aluminium hy droxide, alum inium phosphate, calcium piosphate
Mucosal adjuvants	Heat-labile enterotoxin (LT). cholera toxin (CT),mutant toxins, e.g. LTK63 and L.TR72. microparticles, polymerised liposomes, chitosan
Lipid particles	Emulsions, eg. Freund's (CFA and IFA), ISA 25. 51, 206, SAF. MES9, liposomes, Virosomes, ISCOMS, cochlecates
Particulate adjuvants	PL. G microparticles, poloxamer particles, vins-like particles

6. Modern Adjuvants

In order to solve the pathogen and population-related problems that 21st-century vaccinations encounter, contemporary adjuvants are being created (Wilson-Welder et al., 2009). Therefore, highly developed adjuvants might be able to aid in the prevention of infectious diseases that are significant worldwide but for which effective vaccines have not yet been developed using conventional technology. Improving pathogen detection and evoking a response akin to the innate immune response is a crucial adjuvant role in mitigating the low immunogenicity of subunit vaccines. Adjuvants, when used properly, can extend the duration and breadth of response that can be obtained using pure sub-unit antigen. Improved immune response has a number of practical implications. For example, adjuvants might allow vaccine doses to include less antigen. There may be a reduction in the number of vaccination doses needed to produce immunity as a result of the enhanced immune response. The combined benefits of dosage reduction and antigen sparing may have a significant impact on enhancing the availability of vaccines worldwide. Additionally, adjuvants can boost immune responses in populations—such as young children, the elderly, and immunocompromised individuals—where vaccination responses are generally lower. The selection of adjuvant(s) can influence the innate immune system's initial signal, which in turn can influence the type of adaptive immunological response that is elicited in response to the delivered antigen. This can lead to the preferential activation of specific T-cell responses. According to results that have been published, the adjuvants AS04 and AS03 have direct effects on innate immune cells and effectors rather than adaptive mechanisms. These are typically localized to the injection site and nearby lymph nodes, and they have a brief duration (Didierlaurent et al., 2009).

Adjuvant systems, or adjuvants with many immune-stimulatory molecules, were the next advancement. The creation of the malaria vaccination by GSK served as the proof-of-concept for adjuvant systems. In the mid-1980s, it was discovered that the recombinant RTS,S antigen, which targets the pre-erythrocytic stage of the malaria parasite life cycle, would be a useful antigen for vaccine development. Pre-clinical and human challenge studies were conducted to examine different combinations of immune-stimulatory substances when the adjuvant aluminum proved unsuccessful. Originally, AS02 was chosen, but as clinical development progressed, it became clear that AS01 might offer more advantages than AS02: In comparison to RTS,S/AS02, RTS,S/AS01 appeared to provide stronger clinical protection and elicit higher levels of cell-mediated immune responses in human challenge trials. Children who have received vaccinations have shown to be protected against malaria infection (Bejon et al., 2008). AS01 is the last candidate malaria vaccine that has been tested in Phase III studies. Hepatitis A vaccinations licensed in the mid-1990s were the first to employ an adjuvant other than aluminum; they use a virosome adjuvant system. The spherical phospholipid layers known as virosomes are contained within the lumen or carry bound influenza antigen on their surface. It is possible to modify the virosome's structure and constituent parts to control how it binds to and interacts with innate immune response effectors, hence influencing the

start of subsequent adaptive T-cell and B-cell responses (Moser et al., 2013).

Table 2: Immunologic adjuvant Types

Type of adjuvants	References
Gel-type	
• Aluminum hydroxide or aluminum phosphate	(AT, 1926)
• Caleium phosphate	(AT, 1926; Gupta & Siber, 1994)
Synthetic	
• Nonoie block copolimers	(Hunter et al., 1994)
• Muramyl pepticde analogues	(Cohen et al., 1996)
• Pelyphosphazene	(Cohen et al., 1996; Payne et al., 1998)
• Synthetic polynueleoites	(Harrington et al., 1979)
Particulate	
• Immunostimulatory complexes (ISCOMs)	(Putkonen et al., 1994)
• Liposomes	(Richards et al., 1998)
• Biodegradable microspheres	(Men et al., 1996)
• Saponins 4QS-21	(Newman et al., 1992)
Cytokines	
• IL 2	(Odean et al., 1990)
• IL 12	(Nunberg et al., 1989; Odean et al., 1990)
• INF-gama	(Afonso et al., 1994)
Microbial	
• DNA CpG motifs	(Afonso et al., 1994; Vogel, 2000)
• Monophosphoryl lipid A	(Schneerson et al., 1991)
• Cholera toxin	(Holmgren et al., 1993)
• Escherichia coll heat-labile toxin	(Okahashi et al., 1996)
• Pertussis toxin	(Okahashi et al., 1996)
• Muramyl dipeptide	(Lycke et al., 1992)
Oil-emulsion and emulsifier-based	
• Freund’s incomplete adjuvant	(Dhiman & Khuller, 1997)
• ME59	(Dupuis et al., 1998)
• SAF	(Allison, 1998)

Six additional adjuvants have been added to approved vaccinations in the previous 20 years. Following aluminum, oil-in-water emulsions utilizing oils with higher reactogenicity than Freund's original adjuvant are the adjuvants that are most frequently used. Squalene is a naturally occurring and easily digested oil that is used in a number of oil-in-water emulsions. These emulsions elicit strong cellular and humoral immune responses. Certain adjuvant systems comprise mixtures of adjuvants and are especially engineered to boost T-cell immune responses.

The function of adjuvants in both adaptive and innate immunity The immune system reacts to eliminate an antigen that enters the body. The immune system has two response times: swift and sluggish. The body's initial line of defense is the quickly reacting innate immune system, whereas the slower-acting adaptive immune system offers long-lasting immunological responses (Moser et al., 2013). Innate immunity involves the complement system and phagocytic cells. Antigen-mediated activation of T cells and B lymphocytes with antigen-specific surface receptors starts

adaptive immunological responses. Both CD4 T-helper (Th) cells and CD8 cytotoxic T lymphocytes (CTLs) are distinct T cell subtypes. Th cells are further subdivided into Th1 and Th2 cells, which are significant subpopulations (Schwendener, 2014). Innate immune cells carry pattern-recognition receptors, or PRRs, which help identify harmful microorganisms. PRRs are classified into several families, such as retinoic acid-inducible gene-1 (RIG-1) like receptors (RLRs), toll-like receptors (TLRs), nucleotide oligomerization domain (NOD) like receptors (NLRs), and C-type lectin-like receptors (CLRs). Although internal NLRs and RLRs are present, antigen-presenting cells (APCs) have surface TLRs and CLRs. PAMPs, short for pathogen-associated molecular patterns, are molecular patterns that are present in harmful microorganisms such bacteria, viruses, fungi, and parasites (Haghparast et al., 2016). APCs can use PRRs to identify PAMPs before to or during an antigen's endocytosis. Antigens are recognized, processed by APCs, and their peptides are then incorporated onto major histocompatibility complex (MHC) molecules. Th cells can be activated by antigen peptides complexed with MHC class II molecules. This can lead to the induction of humoral immunity (the generation of opsonic and/or neutralizing antibodies by B cells) and/or cellular immunity (CTL responses). MHC class I-complexed antigen peptides can directly activate CD8 T cells, inducing biological responses (Schijns & Lavelle, 2011).

Adjuvants often work by stimulating PRRs found in immune cells to activate the innate immune system. Most immunostimulatory adjuvants function as ligands for PRRs and, by direct enhancement of an activation pathway, result in the release of cytokines. The cytokines, chemokines, and costimulatory substances that prime, expand, and polarize immune responses are encoded by genes that are expressed as a result of receptor-ligand interactions. Thus, because of inflammasomes, elements of injured or dying host cells also support the action of adjuvant. TLR ligands in particular are strong immunomodulators that affect a range of immunological responses. TLRs are capable of identifying several elements found in bacteria and viruses. TLR ligands belong to distinct types that include lipid, protein, and nucleic acid components. Different TLR ligands cause different patterns of gene expression in cells, which illustrates how specific adaptor molecules like MyD88 (myeloid differentiation primary response gene 88) and TRIF (toll/interleukin-1 receptor domain containing adaptor protein producing interferon-b) produce distinct TLR signaling pathways (Akira, 2011).

Conversely, adjuvants have the ability to stimulate humoral immunity, T cell responses, or both in order to elicit adaptive immunological responses. While monophosphoryl lipid A (MPL) stimulates a Th1 response, immune-stimulating complexes (ISCOMs) work by increasing the generation of antibodies and balancing Th1 and Th2 immune responses (Akira, 2011) and cholera toxin (CT) induces a Th2 response. Whereas Th2 cells stimulate humoral responses to neutralize external antigens, Th1 cells use cell-mediated immunity. The creation of innovative adjuvants that can elicit protective CD8 T cell responses is fraught with difficulties. To improve the development of functional CD8 T cells, an antigen and a potential adjuvant should be combined in a way that allows the antigen to enter the MHC class I processing pathway, which will activate dendritic cells (DCs) and produce type-I interferon (IFN) . A class I MHC-restricted CTL response was elicited by ovalbumin given by fusion-active virosomes, as shown by a study by Bungener et al. The significance of virosomes as the best antigen delivery vehicle for eliciting cellular immunity against encapsulated protein antigens was also emphasized (Bungener et al., 2005).

7. Adjuvant Mechanisms of Action

The majority of adjuvants have poorly understood methods of action because vaccination typically sets off a complex chain reaction and makes it difficult to discern the adjuvant's primary effect. On the other hand, mechanical explanations for some adjuvants, especially those that rely on a "delivery" mechanism, become easier to suggest if one accepts the concept of spatial immune reactivity, which states that antigens that do not reach the nearby lymph nodes do not elicit reactions (Zinkernagel et al., 1997). If antigens do not produce reactions when they reach the lymph nodes, then any adjuvant that enhances antigen transport into the cells that migrate to the lymph node may boost the response. As a subgroup, dendritic cells are thought to be the main cells that circulate

in peripheral organs and serve as "sentinels," absorbing antigens and delivering them to lymph nodes so that T cells can then be exposed to them. While circulating immature DCs are competent at absorbing antigens, mature DCs are effective at delivering antigens to T lymphocytes. Thus, it is thought that in order to generate robust immune responses, it is necessary to promote antigen uptake into dendritic cells, trafficking to lymph nodes, and dendritic cell maturation. Although macrophages can also be used as APCs, dendritic cells are thought to be the most effective type (Zinkernagel et al., 1997).

Adjuvants have different modes of action, therefore the choice of adjuvant to employ with a particular vaccine depends on the desired immunological response as well as the administration method. The first mechanism of adjuvant action to be identified was the depot effect, which happens when gel-type adjuvants, such as aluminum hydroxide, or emulsion-based adjuvants, such as Freund's incomplete adjuvant, associate with antigen and facilitate antigen transport to the draining lymph node, where immune responses are generated. Adjuvants have different modes of action, therefore the choice of adjuvant to employ with a particular vaccine depends on the desired immunological response as well as the administration method. The first mechanism of adjuvant action to be identified was the depot effect, which happens when gel-type adjuvants, such as aluminum hydroxide, or emulsion-based adjuvants, such as Freund's incomplete adjuvant, associate with antigen and facilitate antigen transport to the draining lymph node, where immune responses are generated. Adjuvants that bind to and form particles with tiny antigens, like synthetic peptides, can enhance the immunogenicity of these antigens, which would otherwise be quickly removed from the injection site and draining lymph nodes. Adjuvants may also work by improving the way that antigens are presented. APCs like macrophages and dendritic cells are impacted by immune adjuvants either directly or indirectly. It has recently been demonstrated that dendritic cells internalize the emulsion-based adjuvant MF59 (Baz et al., 2013). Purified saponins, immunostimulatory complexes, and liposomes are examples of novel adjuvants that have been demonstrated to significantly enhance the induction of CD81 cytotoxic T lymphocyte (CTL) responses restricted by the major histocompatibility complex (MHC) class I when compared to when the same antigen is administered alone or in conjunction with conventional alum adjuvants. By introducing antigen into the cytosol for presentation with MHC class I molecules, these adjuvants have the potential to trigger CTL responses. Membrane-active adjuvants that imitate the presentation of antigens during viral infection or live-attenuated vaccine vaccination may be used to transfer antigens into the cytosol (Paavonen et al., 2009).

When antigen is given alone or with alum, it can avoid endosomal antigen delivery and subsequent processing with MHC class II molecules. Antigen supplied to the cytosol can elicit antibody responses predominantly through presentation to CD41 T helper cells . Adjuvants can facilitate the passage of antigen across endosomal membranes into the cytosol following APC consumption of antigen-adjuvant complexes, hence facilitating cytosolic antigen transport and MHC class I presentation. Particulate adjuvants like liposomes can direct antigen toward macrophages or dendritic cells. Adjuvants have the ability to induce APCs to release cytokines that modulate immunity. Adjuvant-induced cytokines influence lymphocytes to primarily stimulate Th1 or Th2 immunological responses (Ahmed et al., 2011; Kundi, 2007). Adjuvants that induce IFN-g and delayed-type hypersensitivity to promote Th1 immune responses also produce IgG subclasses that fix complement and bind with high affinity to Fc-g-I receptors (e.g., IgG2a in mice and IgG1 in humans). These immunoglobulin subtypes are best suited to mediate the complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity effector pathways.

As adjuvants for vaccines, cytokines such as IL-2, IFN-g, granulocyte-macrophage colony stimulating factor, and IL-12 are being studied (Di Pasquale et al., 2015). The immunomodulatory effects of different immunologic adjuvants may be significantly influenced by IL-12, a cytokine that has only been well studied . According to Jankovic et al. (Fox & Haensler, 2013), adding IL-12 to an alum-adsorbed HIV-1 gp120 vaccination caused mice to produce Th1 cytokines as well as

IgG2 and IgG3 antibody responses; the same vaccine, when IL-12 was not added, produced Th2 cytokines and IgG1 antibody responses. Bacterial toxins having adjuvant effect, such as cholera and pertussis toxins, have been shown to increase the generation of IgA and IgE antibodies because they preferentially stimulate Th2-like responses. Th2-like adjuvants have the potential to improve defenses against mucosal viral transmission by increasing IgA synthesis (Fox & Haensler, 2013).




Figure 1: The immune response to vaccination with and without adjuvant (Di Pasquale et al., 2015).

Chemicals, microbiological components, or animal proteins make up the majority of adjuvants. Years of research have left their method of action mostly theoretical. Most seem to work as immunomodulators, to promote antigen stability, or to improve antigen presentation. An adjuvant may function through multiple mechanisms. Adjuvants, for instance, that support the preservation of the antigen's structure can both extend the vaccine's shelf life and enhance its efficacy. This intricate process can be impacted by adjuvants at multiple stages that modify antigen presentation. During an immune response, vaccine antigens need to reach secondary lymphoid tissues, which are usually the lymph nodes. The majority of these antigens are transported to lymph nodes by dendritic cells (Fox & Haensler, 2013). T lymphocytes view epitopes on Major Histocompatibility Complex (MHC) molecules that are processed by these antigen-presenting cells (APCs), B cells, and macrophages. Dendritic cells, macrophages, and B cells also supply additional signals needed to initiate immunization, such as those supplied by the B7 family of molecules. Any adjuvant that improves these cells' capacity to absorb antigens, boosts their production of MHC or costimulatory molecules, or promotes their migration into lymph nodes can boost immunity. Dendritic cells, macrophages, and B cells also supply additional signals needed to initiate immunization, such as those supplied by the B7 family of molecules. Any adjuvant that improves these cells' capacity to absorb antigens, boosts their production of MHC or costimulatory molecules, or promotes their migration into lymph nodes can boost immunity. Adjuvants that trap antigen at the injection site and supply local APCs with it continuously seem to work. The liver's ability to eliminate the antigen may be hampered by this depot effect. Short-term (8–10 days) depots that are adequate to boost immunity can be formed using oil emulsions, such as Freund's adjuvants. Recent developments in microparticle adjuvants have the potential to deliver antigens in pulsed dosages and establish long-term depots lasting 1-6 months. The liver's Kupffer cells may be saturated by other adjuvants.

Adjuvants like these have the potential to enhance the quantity of antigen that reaches APCs by decreasing hepatic absorption of the antigen. Diethyl aminoethyl (DEAE) dextran and high-molecular-weight sulfated dextran are two examples of derivatized polysaccharide adjuvants for which this process has been proposed (Fox & Haensler, 2013).

Adjuvants can enhance the targeting of antigens to APCs. Particulate adjuvants that encourage the development of aggregates, like alum or aluminum salts, make them easier for phagocytosis. By binding to carbohydrate receptors, carbohydrates polymers like mannan or acemannan may be able to direct antigens to APCs. Carrier proteins such as keyhole limpet hemocyanin (KLH), diphtheria or tetanus toxoid, and bovine serum albumin may assist deliver haptens or carbohydrate antigens by recruiting T-helper cells. Additionally, it seems that certain adjuvants direct the antigen into particular APC compartments and affect the CTL response's activation. Interaction with antigens contained in MHC II or MHC I molecules, respectively, triggers T-helper cells and CTL responses. While there is some "cross-presentation" (or crossing of antigens between routes), antigens displayed in MHC II molecules often originate outside of APCs and are taken up by phagocytosis, while antigens shown in MHC I molecules typically originate inside the APC cytoplasm. The majority of adjuvants are capable of efficiently boosting humoral immunity and helper cells. Certain substances, including liposomes, seem to also carry antigens to pathways that result in MHC I molecule presentation and the activation of a CTL response and Cross-presentation might be crucial in some circumstances for producing CTLs.

An further mode of action is immunomodulation. Immunomodulators modify the cytokine network to activate the immune system. Certain adjuvants stimulate the immune system overall and cytokines in particular. Adjuvants typically affect the kind of immunity by raising the levels of specific cytokines and lowering those of other cytokines. Interleukin-2 (IL-2), interferon gamma (INF-g), and IL-12 are cytokines that are linked to Th1 responses in T-helper cells and cell-mediated immunity (CMI). T-helper type 2 (Th2) responses and humoral immunity are linked to IL-4, IL-5, IL-6, IL-13, and potentially IL-10. Adjuvants such as saponins can increase CMI to an antigen that would typically generate just antibodies by altering the balance of these two sets of cytokines. Certain adjuvants that modulate immunity enhance the expression of MHC or costimulatory molecules on antigen-presenting cells (APCs), either by direct means or by inducing cytokines (Fox & Haensler, 2013).

Summary

Several artificial and natural adjuvants can be added to animal immunizations to increase their effectiveness. Some ingredients, such as emulsions, carbomers, cytokines, and polyphosphazenes, have already been included in goods under license, while others, such as aluminum compounds, saponins, and carbomers, are presently being evaluated in experiments. Numerous considerations should be made when selecting or developing adjuvants for animal vaccines, including animal safety, compliance with food safety laws, efficacy in the target animal species, induction of a prompt and durable protective immunity, viability for production scaling up, and, last but not least, cost effectiveness. Even while modern vaccination adjuvants effectively generate humoral or antibody-mediated immunity, cell-mediated immunity is still required for effective defense against many diseases that affect people and animals today, such as tuberculosis and malaria. The available vaccination adjuvants, their effect on eliciting immunological responses, and vaccine adjuvants showing promise in the most current studies are all thoroughly analyzed. Adjuvant vaccines can have a variety of beneficial benefits. These include: (1) increasing the likelihood that vaccinations will reach higher levels of immunogenicity and protective efficacy (e.g., alum for bacterial and viral vaccines); (2) reducing the dose of antigens needed for vaccinations to be effective (e.g., MF59 for influenza vaccines); (3) accelerating and reducing the number of vaccinations needed to achieve effectiveness (e.g., AS04 for hepatitis B vaccine); (4) broadening the repertoire of antibody responses (e.g., MF59 for influenza vaccinations); and (5) modulating the phenotype of T cell responses. The variety of disease targets, small molecule compounds, and patient populations have

created an environment that is conducive to the discovery and development of novel adjuvants.

References:

Afonso, L. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., & Scott, P. (1994). The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science, 263(5144), 235-237.

Ahmed, S. S., Plotkin, S. A., Black, S., & Coffman, R. L. (2011). Assessing the safety of adjuvanted vaccines. Science translational medicine, 3(93), 93rv92-93rv92.

Akira, S. (2011). Innate immunity and adjuvants. Philosophical Transactions of the Royal Society B: Biological Sciences, 366(1579), 2748-2755.

Allison, A. (1998). The mode of action of immunological adjuvants. Developments in biological standardization, 92, 3-11.

AT, G. (1926). The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol, 29, 38-40.

Aucouturier, J., Dupuis, L., & Ganne, V. (2001). Adjuvants designed for veterinary and human vaccines. Vaccine, 19(17-19), 2666-2672.

Baz, M., Luke, C. J., Cheng, X., Jin, H., & Subbarao, K. (2013). H5N1 vaccines in humans. Virus research, 178(1), 78-98.

Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., & Dubois, M.-C. (2008). Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. New England Journal of Medicine, 359(24), 2521-2532.

Bowersock, T. L., & Martin, S. (1999). Vaccine delivery to animals. Advanced drug delivery reviews, 38(2), 167-194.

Bungener, L., Huckriede, A., de Mare, A., de Vries-Idema, J., Wilschut, J., & Daemen, T. (2005). Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine, 23(10), 1232-1241.

Chroboczek, J., Szurgot, I., & Szolajska, E. (2014). Virus-like particles as vaccine. Acta Biochimica Polonica, 61(3).

Coffman, R. L., Sher, A., & Seder, R. A. (2010). Vaccine adjuvants: putting innate immunity to work. Immunity, 33(4), 492-503.

Cohen, L. Y., Bahr, G. M., Darcissac, E. C., & Parant, M. A. (1996). Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides. Cellular immunology, 169(1), 75-84.

Dhiman, N., & Khuller, G. (1997). Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H 37 Ra. Medical microbiology and immunology, 186, 45-51.

Di Pasquale, A., Preiss, S., Tavares Da Silva, F., & Garçon, N. (2015). Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines, 3(2), 320-343.

Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., & Schiavetti, F. (2009). AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. The Journal of immunology, 183(10), 6186-6197.

Dupuis, M., Murphy, T. J., Higgins, D., Ugozzoli, M., van Nest, G., Ott, G., & McDonald, D. M. (1998). Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cellular immunology, 186(1), 18-27.

Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974). Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and biophysical research communications, 59(4), 1317-1325.

Fox, C. B., & Haensler, J. (2013). An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert review of vaccines, 12(7), 747-758.

Freund, J., Casals, J., & Hosmer, E. P. (1937). Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proceedings of the society for experimental biology and medicine, 37(3), 509-513.

Gupta, R. K., & Siber, G. R. (1994). Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals, 22(1), 53-63.

Haghparast, A., Zakeri, A., Ebrahimian, M., & Ramezani, M. (2016). Targeting pattern recognition receptors (PRRs) in nano-adjuvants: current perspectives. Current Bionanotechnology (Discontinued), 2(1), 47-59.

Harrington, D., Crabbs, C., Hilmas, D., Brown, J., Higbee, G., Cole Jr, F., & Levy, H. (1979). Adjuvant Effects of Low Doses of a Nuclease-Resistant Derivative of Polyinosinic Acid· Polycytidylic Acid on Antibody Responses of Monkeys to Inactivated Venezuelan Equine Encephalomyelitis Virus Vaccine. Infection and immunity, 24(1), 160-166.

Holmgren, J., Lycke, N., & Czerkinsky, C. (1993). Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systems. Vaccine, 11(12), 1179-1184.

Hunter, R., McNicholl, J., & Lal, A. (1994). Mechanisms of action of nonionic block copolymer adjuvants. AIDS research and human retroviruses, 10, S95-98.

Kundi, M. (2007). New hepatitis B vaccine formulated with an improved adjuvant system. Expert review of vaccines, 6(2), 133-140.

Lee, S., & Nguyen, M. T. (2015). Recent advances of vaccine adjuvants for infectious diseases. Immune network, 15(2), 51.

Lindblad, E. B., Elhay, M. J., Silva, R., Appelberg, R., & Andersen, P. (1997). Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infection and immunity, 65(2), 623-629.

Lycke, N., Tsuji, T., & Holmgren, J. (1992). The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. European journal of immunology, 22(9), 2277-2281.

Marrack, P., McKee, A. S., & Munks, M. W. (2009). Towards an understanding of the adjuvant action of aluminium. Nature Reviews Immunology, 9(4), 287-293.

Men, Y., Gander, B., Merkle, H. P., & Corradin, G. (1996). Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine, 14(15), 1442-1450.

Moser, C., Müller, M., Kaeser, M. D., Weydemann, U., & Amacker, M. (2013). Influenza virosomes as vaccine adjuvant and carrier system. Expert review of vaccines, 12(7), 779-791.

Newman, M. J., Wu, J., Gardner, B. H., Munroe, K. J., Leombruno, D., Recchia, J., Kensil,

C., & Coughlin, R. (1992). Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. Journal of immunology (Baltimore, Md.: 1950), 148(8), 2357-2362.

Nunberg, J. H., Doyle, M. V., York, S. M., & York, C. J. (1989). Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proceedings of the National Academy of Sciences, 86(11), 4240-4243.

O'HAGAN, D. T. (1998). Conference science medal lecture: recent advances in vaccine adjuvants for systemic and mucosal administration. Journal of pharmacy and pharmacology, 50(1), 1-10.

Odean, M., Frane, C., Van derVieren, M., Tomai, M., & Johnson, A. (1990). Involvement of gamma interferon in antibody enhancement by adjuvants. Infection and immunity, 58(2), 427-432.

Okahashi, N., Yamamoto, M., Vancott, J. L., Chatfield, S. N., Roberts, M., Bluethmann, H., Hiroi, T., Kiyono, H., & McGhee, J. R. (1996). Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infection and immunity, 64(5), 1516-1525.

Paavonen, J., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J. C., & Skinner, S. R. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet, 374(9686), 301-314.

Park, J. Y., Kim, M.-G., Shim, G., & Oh, Y.-K. (2016). Lipid-based antigen delivery systems. Journal of Pharmaceutical Investigation, 46, 295-304.

Payne, L. G., Jenkins, S. A., Woods, A. L., Grund, E. M., Geribo, W. E., Loebelenz, J. R., Andrianov, A. K., & Roberts, B. E. (1998). Poly [di (carboxylatophenoxy) phosphazene](PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine, 16(1), 92-98.

Putkonen, P., Nilsson, C., Walther, L., Ghavamzadeh, L., Hild, K., Broliden, K., Biberfeld, G., & Thorstensson, R. (1994). Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys. Journal of medical primatology, 23(2-3), 89-94.

Ramon, G. (1925). Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique. Bull Soc Centr Med Vet, 101, 227-234.

Ramon, G. (1926). Procedes pour acroitre la production des antitoxins. Ann Inst Pasteur, 40, 1-10.

Richards, R. L., Rao, M., Wassef, N. M., Glenn, G. M., Rothwell, S. W., & Alving, C. R. (1998). Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen. Infection and immunity, 66(6), 2859-2865.

Schijns, V. E., & Lavelle, E. C. (2011). Trends in vaccine adjuvants. Expert review of vaccines, 10(4), 539-550.

Schneerson, R., Fattom, A., Szu, S., Bryla, D., Ulrich, J., Rudbach, J., Schiffman, G., & Robbins, J. (1991). Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. Journal of immunology (Baltimore, Md.: 1950), 147(7), 2136-2140.

Schwendener, R. A. (2014). Liposomes as vaccine delivery systems: a review of the recent advances. Therapeutic advances in vaccines, 2(6), 159-182.

Vogel, F. R. (2000). Improving vaccine performance with adjuvants. Clinical Infectious Diseases, 30(Supplement_3), S266-S270.

Vogel, F. R., & Powell, M. F. (1995). A compendium of vaccine adjuvants and excipients. Vaccine design: the subunit and adjuvant approach, 141-228.

Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009). Vaccine adjuvants: current challenges and future approaches. Journal of pharmaceutical sciences, 98(4), 1278-1316.

Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kündig, T., & Hengartner, H. (1997). Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunological reviews, 156(1), 199-209.

About the Author

Muhammad Muzammil Nazir[1], Asma Ashraf [1], Derya Karatas Yeni[2]

[1]Department of Zoology, Government College University, Faisalabad 38000, Pakistan; muzammilnazir51@gmail.com (M.M.N) asmabinm@gmail.com

[2]Department of Microbiology, Veterinary Faculty, University of Necmettin Erbakan, Ereğli, 42310, Konya,Turkey; vhekimderya@hotmail.com (D. K.Y.)

Corresponding author: asmabinm@gmail.com Prof. Dr. Asma Ashraf +92332-6735319

To Cite This Chapter

NAZIR, MM, et al. (2024). Vaccine Adjuvants: Enhancing Immune Response in Livestock Vaccination. In Animal Production and Health (pp.377-390). ISRES Publishing.